The ADAURA trial showed both overall survival (OS) and disease-free survival (DFS) benefits with the use of the EGFR tyrosine kinase inhibitor (TKI) osimertinib as adjuvant treatment post-surgical resection of stage IB-III EGFR-mutant NSCLC.6 Recently, the ALINA study also showed an improvement in DFS with adjuvant alectinib compared to chemotherapy in patients with resected early-stage ALK-positive NSCLC.7 However, the efficacy of targeted therapies in NSCLC with other rare driver mutations in the adjuvant setting remains less well-defined. Here, ALK is linked to non-small cell lung carcinoma.